Multi-Country Trial Finds Shorter Malaria Treatment Regimens More Effective Than Standard Course
A multicenter EFFORT Trial published in The Lancet Infectious Diseases found that 7-day high-dose primaquine and single-dose tafenoquine significantly reduced P. vivax malaria recurrence compared to the standard 14-day low-dose primaquine regimen. The trial, conducted across Ethiopia, Pakistan, Indonesia, and Cambodia, supports WHO guidelines and potential geographic expansion of tafenoquine use.